Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
Surrozen reported Q2 2026 revenue of $5.0 million, driven by a milestone payment from partner Boehringer Ingelheim, and ended the quarter with $102.0 million in cash. The company remains on track to submit an IND for SZN-8141 in diabetic macular edema by the end of Q3 2026 and initiate the DUET Phase 1b/2a study by year-end, with initial data anticipated in the second half of 2027. In a significant IP development, the U.S.
Key figures
- Eps
- 2.75
- Revenue
- $5.0 million
- Net income
- $50.2 million
- Ga expenses
- $6.9 million
- Rd expenses
- $8.5 million
- Cash position
- $102.0 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.